MCP-1/CCL2 is a potential target for DKD treatment, as established nephroprotective therapies, such as RAAS inhibition, have been demonstrated to reduce renal MCP-1 expression and macrophage recruitment in experimental diabetic nephropathy [53] as well as to ameliorate albuminuria, slow GFR decline and decrease urinary MCP-1/CCL2 in type II DKD patients [54]. Here, CCL2 is linked to diabetic kidney disease.